Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
The company was founded in 2004 and is headquartered in Coral Gables, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.72 Increased by +17.24% | -0.85 Increased by +15.29% |
| Mar 19, 24 | -0.84 Increased by +40.43% | -0.83 Decreased by -1.20% |
| Nov 8, 23 | -0.73 Increased by +44.27% | -0.91 Increased by +19.78% |
| Aug 8, 23 | -0.84 Increased by +36.84% | -0.90 Increased by +6.67% |
| May 11, 23 | -0.87 Increased by +37.86% | -0.89 Increased by +2.25% |
| Mar 23, 23 | -1.41 Increased by +21.67% | -1.33 Decreased by -6.02% |
| Nov 10, 22 | -1.31 Increased by +46.31% | -1.45 Increased by +9.66% |
| Aug 11, 22 | -1.33 Increased by +14.74% | -1.27 Decreased by -4.72% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.00 M Increased by +45.13% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -25.30 M Increased by +26.35% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -24.49 M Increased by +40.55% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -37.19 M Decreased by -8.17% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -40.10 M Increased by +5.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -34.36 M Decreased by -29.40% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -41.19 M Decreased by -85.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -34.38 M Decreased by -65.58% | Decreased by N/A% Decreased by N/A% |